Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Octapharma AG
DescriptionMixture of human Factor VIII and human von Willebrand factor (vWF)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentMarketed
Standard IndicationBleeding
Indication DetailsPrevent surgical bleeding in patients with Type III von Willebrand Disease (vWD); Treat spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (vWD) as well as patients with mild to moderate VWD in whom desmopressin is either ineffective or contraindicated; Treat von Willebrand disease (vWD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today